These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 29861388)

  • 61. The role of polygenic susceptibility to obesity among carriers of pathogenic mutations in MC4R in the UK Biobank population.
    Chami N; Preuss M; Walker RW; Moscati A; Loos RJF
    PLoS Med; 2020 Jul; 17(7):e1003196. PubMed ID: 32692746
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
    Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
    Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 65. Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation.
    Elkhenini HF; New JP; Syed AA
    Clin Obes; 2014 Apr; 4(2):121-4. PubMed ID: 25826735
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Liraglutide reduces body weight by upregulation of adenylate cyclase 3.
    Li Z; Liang Y; Xia N; Lai Y; Pan H; Zhou S; Jiang F; He Y
    Nutr Diabetes; 2017 May; 7(5):e265. PubMed ID: 28481334
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
    Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
    Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity.
    Matias I; Lehmann EW; Zizzari P; Byberg S; Cota D; Torekov SS; Quarta C
    J Endocrinol Invest; 2024 May; 47(5):1289-1294. PubMed ID: 37924474
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
    J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries.
    Niafar M; Pourafkari L; Porhomayon J; Nader N
    Arch Gynecol Obstet; 2016 Mar; 293(3):509-15. PubMed ID: 26660657
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC; Colomo N; Tinahones FJ
    Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.
    Fitch A; Ingersoll AB
    Postgrad Med; 2021 Apr; 133(3):310-319. PubMed ID: 33151791
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dietary Protein Modifies the Effect of the
    Huang T; Zheng Y; Hruby A; Williamson DA; Bray GA; Shen Y; Sacks FM; Qi L
    J Nutr; 2017 Mar; 147(3):439-444. PubMed ID: 28148682
    [No Abstract]   [Full Text] [Related]  

  • 76. [Prevalence of melanocortin 4 receptor (MC4R) mutations and polymorphismsin consecutively ascertained obese children and adolescents from a pediatric health care utilization population].
    Zakel UA; Wudy SA; Heinzel-Gutenbrunner M; Görg T; Schäfer H; Gortner L; Blum WF; Hebebrand J; Hinney A
    Klin Padiatr; 2005; 217(4):244-9. PubMed ID: 16032553
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response.
    Roubert P; Dubern B; Plas P; Lubrano-Berthelier C; Alihi R; Auger F; Deoliveira DB; Dong JZ; Basdevant A; Thurieau C; Clément K
    J Endocrinol; 2010 Nov; 207(2):177-83. PubMed ID: 20696697
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Obesity caused by melanocortin-4 receptor mutations].
    van den Berg L; Glorie-Docter M; van den Akker E; Delemarre-van de Waal HA
    Ned Tijdschr Geneeskd; 2012; 156(32):A4548. PubMed ID: 22871247
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review.
    Jensterle M; Rizzo M; Haluzík M; Janež A
    Adv Ther; 2022 Jun; 39(6):2452-2467. PubMed ID: 35503498
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Monogenic Obesity; Using Drugs to Bypass the Problem.
    Coll AP
    Cell Metab; 2018 Jul; 28(1):1-2. PubMed ID: 29972795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.